Added to YB: 2026-10-07
Pitch date: 2026-10-02
QURE [bullish]
uniQure N.V.
+1.08%
current return
Author Info
Back of the Napkin Bios shares highly digestible high conviction names in bio land. Sign up for the newsletter.
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$1.6B
Pitch Price
$22.28
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.50
P/E
-5.71
EV/Sales
71.84
Sector
Biotechnology
Category
special_situation
The Three-Year Question - uniQure N.V.
QURE (update): uniQure’s AMT-130 case rests on the three-year analysis FDA said could primarily support the accelerated-approval BLA: cUHDRS decline slowed 75% (p=.003) and TFC decline 60% (p=.033), with expanded results strengthening both. Although four-year cUHDRS slowed only 44% and was not significant, TFC retained 61% slowing (nominal p=.008) and high dose outperformed low dose. The main uncertainties are the 12-patient cohort and external control; upcoming Q-Motor and imaging data could corroborate or challenge the functional signal.
Read full article (17 min)